SCHEMBL3553340

SCHEMBL3553340

CCCCc1ccc(S(=O)(=O)Nc2ccc(OCCOc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
FFAR1 O14842 1/20 0.55
FFAR4 Q5NUL3 1/20 0.55
TDP1 Q9NUW8 2/20 0.53
POLB P06746 1/20 0.53
METAP2 P50579 1/20 0.52
WDR5 P61964 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 1/20 0.51
ALDH1A1 P00352 1/20 0.50
LIMK2 P53671 1/20 0.48
CACNA1B Q00975 1/20 0.48
PKM P14618 2/20 0.48
GHSR Q92847 1/20 0.48
MCL1 Q07820 1/20 0.48
BCL2A1 Q16548 1/20 0.48
HTT P42858 2/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560203 0.94 TDP1 (0.54) SMN1; SMN2LMNATDP1POLBMETAP2
SCHEMBL3562134 0.94 SMN1; SMN2 (0.63) SMN1; SMN2LMNATDP1WDR5MEN1
SCHEMBL3565129 0.90 MEN1 (0.55) SMN1; SMN2LMNATDP1POLBMETAP2
SCHEMBL3561368 0.87 SMN1; SMN2 (0.54) SMN1; SMN2LMNAFFAR1FFAR4TDP1
SCHEMBL3558986 0.86 ALDH1A1 (0.63) SMN1; SMN2LMNATDP1POLBMEN1
SCHEMBL3561329 0.86 SMN1; SMN2 (0.58) SMN1; SMN2LMNAFFAR1FFAR4TDP1
SCHEMBL3554403 0.86 TDP1 (0.60) SMN1; SMN2LMNAFFAR1FFAR4TDP1
SCHEMBL3561723 0.86 PGR (0.57) SMN1; SMN2LMNAPOLBMEN1KMT2A
SCHEMBL3551452 0.86 SMN1; SMN2 (0.63) SMN1; SMN2LMNAFFAR1FFAR4TDP1
SCHEMBL3559276 0.86 AR (0.61) SMN1; SMN2LMNAFFAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SMN1; SMN2 4522/4885LMNA 2120/4885FFAR1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.